In next-gen BTK bat­tle, Ab­b­Vie and J&J tout piv­otal da­ta back­ing Im­bru­vi­ca as a com­bo treat­ment

Last week, As­traZeneca took a swing at J&J and Ab­b­Vie’s first-gen­er­a­tion BTK in­hibitor Im­bru­vi­ca in the blood can­cer chron­ic lym­pho­cyt­ic leukemia with long-term da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.